This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amarin Announces Additional Vascepa(R) (icosapent Ethyl) Supplier

BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 11, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the development of therapeutics to improve cardiovascular health, today announced the addition of an exclusive consortium of companies led by Slanmhor Pharmaceutical, Inc. (Slanmhor) to its planned active pharmaceutical ingredient (API) global supply chain for Vascepa® (icosapent ethyl) capsules. Slanmhor was spun-out from Ocean Nutrition Canada (ONC) prior to the May 2012 acquisition of ONC by Royal DSM N.V. (DSM), a global leader in life sciences and materials sciences. Amarin now has a total of four API suppliers for Vascepa API for Amarin to utilize to support the global commercialization of Vascepa, subject to appropriate regulatory approvals.

Slanmhor, based in Halifax, Nova Scotia, Canada, is led by CEO Robert Orr, a pioneer and industry leader in the omega-3 manufacturing industry and the former Chairman and CEO of ONC, the world's largest supplier of concentrated omega-3 fatty acid products. In producing API for Amarin, Slanmhor, through exclusive agreements, is collaborating with DSM/ONC for the supply of intermediate omega-3 oil, and Novasep, a global leader in purification technologies and API manufacturing. The Slanmhor/DSM/Novasep consortium offers one of the most well established omega-3 current good manufacturing practice (cGMP) API manufacturing solutions globally and further solidifies Amarin's capability to reliably source Vascepa.

"We have found very few companies with the technical ability to produce Vascepa to our unique specifications. The addition of this exclusive Slanmhor consortium rounds out our global diversity and expands our potential capacity to meet the anticipated market demand for Vascepa," said Joseph Zakrzewski, Chairman and Chief Executive Officer of Amarin. "Pooling the resources of four of the world's leading omega-3 API manufacturers supports the commercial potential of Vascepa by providing for additional scalability and reliability to Amarin's supply chain."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs